drugset / Trial / NCT00024427

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

NCT00024427 ↗

Phase 3 Completed 250 enrolled Wellstat Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy. It is not yet known which chemotherapy regimen is more effective in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil plus triacetyluridine with that of gemcitabine in treating patients who have locally advanced or metastatic pancreatic cancer that cannot be treated with surgery.

Timeline

Start
2001-02
Primary completion
2006-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — Intravenous
Subject fluorouracil Small molecule — Intravenous
Subject triacetyluridine Unknown 6 g Oral